Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Ocugen < Previous 1 2 Next > Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease June 21, 2024 From Ocugen Via GlobeNewswire Tickers OCGN Ocugen, Inc. Announces First Patient Dosed in Phase 3 liMeliGhT Clinical Trial for OCU400—First Gene Therapy in Phase 3 with a Broad Retinitis Pigmentosa Indication June 20, 2024 From Ocugen Via GlobeNewswire Tickers OCGN Data and Safety Monitoring Board Approves Simultaneous Enrollment in Cohort 3 and Phase 2 Initiation in OCU410 ArMaDa study for Geographic Atrophy May 31, 2024 From Ocugen Via GlobeNewswire Tickers OCGN Ocugen to Present at BIO International Convention 2024 May 29, 2024 From Ocugen Via GlobeNewswire Tickers OCGN Ocugen Set to Join Russell 3000® Index Effective June 28, 2024 May 28, 2024 From Ocugen Via GlobeNewswire Tickers OCGN Ocugen Announces CSO to Present on Modifier Gene Therapy at International Society for Cell & Gene Therapy 2024 May 20, 2024 From Ocugen Via GlobeNewswire Tickers OCGN Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy May 15, 2024 From Ocugen Via GlobeNewswire Tickers OCGN Ocugen Provides Business Update with First Quarter 2024 Financial Results May 14, 2024 From Ocugen Via GlobeNewswire Tickers OCGN Ocugen Announces Distribution of Series C Preferred Stock to Holders of its Common Stock May 10, 2024 From Ocugen Via GlobeNewswire Tickers OCGN Ocugen to Present at May 2024 Investor Conferences May 10, 2024 From Ocugen Via GlobeNewswire Tickers OCGN Ocugen to Host Conference Call on Tuesday, May 14 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2024 Financial Results May 03, 2024 From Ocugen Via GlobeNewswire Tickers OCGN Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina World Congress May 02, 2024 From Ocugen Via GlobeNewswire Tickers OCGN Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024 April 29, 2024 From Ocugen Via GlobeNewswire Tickers OCGN UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting April 26, 2024 From Ocugen Via GlobeNewswire Tickers OCGN Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting April 26, 2024 From Ocugen Via GlobeNewswire Tickers OCGN Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy April 19, 2024 From Ocugen Via GlobeNewswire Tickers OCGN Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets April 12, 2024 From Ocugen Via GlobeNewswire Tickers OCGN Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication April 10, 2024 From Ocugen Via GlobeNewswire Tickers OCGN Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication April 08, 2024 From Ocugen Via GlobeNewswire Tickers OCGN Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic Atrophy April 05, 2024 From Ocugen Via GlobeNewswire Tickers OCGN Ocugen Provides Business Update with Certain Financials for the Year Ending 2023 April 02, 2024 From Ocugen Via GlobeNewswire Tickers OCGN Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST—a Modifier Gene Therapy—in GARDian Study for Stargardt Disease April 01, 2024 From Ocugen Via GlobeNewswire Tickers OCGN Ocugen to Host Conference Call on Tuesday, April 2 at 8:30 A.M. ET to Provide Business Update with Certain Financials for the Year Ending 2023 April 01, 2024 From Ocugen Via GlobeNewswire Tickers OCGN Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer March 18, 2024 From Ocugen Via GlobeNewswire Tickers OCGN Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410 March 13, 2024 From Ocugen Via GlobeNewswire Tickers OCGN Ocugen to Present at Investing in Cures Summit March 06, 2024 From Ocugen Via GlobeNewswire Tickers OCGN Ocugen Clinical Showcase Webcast Now Available February 28, 2024 From Ocugen Via GlobeNewswire Tickers OCGN Ocugen, Inc. Announces Dosing Completion of Subjects with Stargardt in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST February 22, 2024 From Ocugen Via GlobeNewswire Tickers OCGN Ocugen to Present at 2024 BIO CEO & Investor Conference February 21, 2024 From Ocugen Via GlobeNewswire Tickers OCGN Ocugen to Host Clinical Showcase in New York City on Wednesday, February 21, 2024 February 14, 2024 From Ocugen Via GlobeNewswire Tickers OCGN < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.